Reduced-Dose Angiography CT Imaging

Overview

About this study

3D angiography (3DA) imaging is a valuable method for assessing cardiovascular anatomy prior to and following trans-catheter intervention.  Current 3DA contributes substantially to the overall patient radiation dose for these procedures.  The purpose of this work is to assess the clinical efficacy of reduced radiation dose 3DA.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients scheduled for interventional procedure to treat congenital or structural heart disease
  • Pediatric patients between the ages 13 and 18 scheduled for interventional procedure to treat congenital or structural heart disease
  • Normal kidney renal function as determined by serum creatinine concentration, creatinine clearance, and/or glomerular filtration rate
  • Written informed consent from the patient and/or the patient’s parent/guardian (for patients 13-17 years old) to participate in the study

Exclusion Criteria:

  • Women who are pregnant

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Nathaniel Taggart, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions